Westwood Holdings Group Inc. Has $1.43 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Westwood Holdings Group Inc. grew its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 397.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,191 shares of the biopharmaceutical company's stock after acquiring an additional 20,124 shares during the period. Westwood Holdings Group Inc.'s holdings in Bristol-Myers Squibb were worth $1,425,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of BMY. Ameritas Advisory Services LLC grew its position in shares of Bristol-Myers Squibb by 9.4% in the 4th quarter. Ameritas Advisory Services LLC now owns 15,807 shares of the biopharmaceutical company's stock valued at $894,000 after acquiring an additional 1,357 shares during the period. Annex Advisory Services LLC boosted its holdings in shares of Bristol-Myers Squibb by 6.0% during the 4th quarter. Annex Advisory Services LLC now owns 6,796 shares of the biopharmaceutical company's stock worth $384,000 after buying an additional 384 shares during the period. Diversify Wealth Management LLC boosted its holdings in shares of Bristol-Myers Squibb by 10.0% during the 4th quarter. Diversify Wealth Management LLC now owns 14,123 shares of the biopharmaceutical company's stock worth $788,000 after buying an additional 1,286 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Bristol-Myers Squibb by 4.0% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 8,687 shares of the biopharmaceutical company's stock worth $491,000 after buying an additional 332 shares during the period. Finally, Zhang Financial LLC boosted its holdings in shares of Bristol-Myers Squibb by 42.3% during the 4th quarter. Zhang Financial LLC now owns 5,826 shares of the biopharmaceutical company's stock worth $330,000 after buying an additional 1,732 shares during the period. Institutional investors own 76.41% of the company's stock.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.07% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Price Performance

BMY stock traded down $0.15 during trading on Friday, reaching $46.88. 8,401,343 shares of the company were exchanged, compared to its average volume of 13,167,263. The company has a 50-day moving average of $51.79 and a two-hundred day moving average of $55.71. The company has a market capitalization of $95.40 billion, a price-to-earnings ratio of -10.61, a P/E/G ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm's quarterly revenue was down 5.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($4.40) EPS. As a group, equities analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.29%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is 92.88%.

Analysts Set New Price Targets

BMY has been the subject of several research analyst reports. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. UBS Group dropped their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Finally, Wells Fargo & Company lifted their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.